Goldman Sachs Group Inc Eiger Bio Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	SELL	$0.55 - $1.26 $138,894 - $318,195	-252,536 Reduced 95.57%	11,706 $8,000
Q2 2023 Aug 14, 2023	SELL	$0.55 - $1.26 $138,894 - $318,195	-252,536 Reduced 95.57%	11,706 $8,000
Q1 2023 May 14, 2024	BUY	$0.89 - $2.52 $83,344 - $235,987	93,646 Added 54.89%	264,242 $237,000
Q1 2023 May 11, 2023	BUY	$0.89 - $2.52 $83,344 - $235,987	93,646 Added 54.89%	264,242 $237,000
Q4 2022 May 14, 2024	SELL	$1.02 - $7.48 $31,827 - $233,398	-31,203 Reduced 15.46%	170,596 $201,000
Q4 2022 Feb 13, 2023	SELL	$1.02 - $7.48 $31,827 - $233,398	-31,203 Reduced 15.46%	170,596 $201,000
Q3 2022 May 14, 2024	SELL	$6.04 - $9.66 $333,250 - $532,980	-55,174 Reduced 21.47%	201,799 $1.52 Million
Q3 2022 Nov 10, 2022	SELL	$6.04 - $9.66 $333,250 - $532,980	-55,174 Reduced 21.47%	201,799 $1.52 Million
Q2 2022 May 14, 2024	BUY	$4.99 - $8.96 $1.28 Million - $2.3 Million	256,973 New	256,973 $1.62 Million
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $65,383 - $117,402	-13,103 Reduced 4.85%	256,973 $1.62 Million
Q1 2022 May 16, 2022	SELL	$3.84 - $9.74 $440,052 - $1.12 Million	-114,597 Reduced 29.79%	270,076 $2.24 Million
Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $18,933 - $30,286	3,698 Added 0.97%	384,673 $2 Million
Q3 2021 Nov 10, 2021	BUY	$6.68 - $9.1 $2.54 Million - $3.47 Million	380,975 New	380,975 $2.55 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.